Long-term magnesium supplementation improves glucocorticoid metabolism: A post-hoc analysis of an intervention trial
Schutten JC, Joris PJ, Minović I, Post A, van Beek AP, de Borst MH, Mensink RP, Bakker SJL
Clinical endocrinology · 18 citas
Etiquetas de revisión
Financiado por la industriaSolo mecanismosDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Solo mecanismos
Quién lo pagó
- Financiación
- Financiado por la industria
- Organización sin fines de lucro
- Nierstichting
Según 1 financiador declarado y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2020-10-08 · Clin Endocrinol (Oxf) · vol. 94 · número 2 · págs. 150–157
- Editorial
- Wiley
- Citado
- 25 citas · más que el 76% de estudios similares · 1.2× el promedio de su campo
- Referencias
- 38 trabajos
- Acceso
- Acceso abierto (revista híbrida) · CC-BY-NC
- Áreas de investigación
- Magnesium in Health and Disease · Hormonal Regulation and Hypertension · Stress Responses and Cortisol
- Palabras clave
- Cortisone, Endocrinology, Internal medicine, Glucocorticoid, Medicine, Excretion, Placebo, Chemistry, Urine
- MeSH
- humans, magnesium, tetrahydrocortisone, cortisone, hydrocortisone, glucocorticoids, dietary supplements, aged, middle aged, female, male
8 autores
- Joëlle C. Schutten🇳🇱 · autor de correspondenciaUniversity Medical Center Groningen; University of Groningen
- Peter J. Joris🇳🇱Maastricht University Medical Centre; Maastricht University
- Isidor Minović🇳🇱University Medical Center Groningen; University of Groningen
- Adrian Post🇳🇱University Medical Center Groningen; University of Groningen
- André P. van Beek🇳🇱University Medical Center Groningen; University of Groningen
- Martin H. de Borst🇳🇱University Medical Center Groningen; University of Groningen
- Ronald P. Mensink🇳🇱Maastricht University Medical Centre; Maastricht University
- Stephan J. L. Bakker🇳🇱University Medical Center Groningen; University of Groningen
Resumen
El texto original del estudio, en el idioma en que se publicó.
Objective
Increasing magnesium intake might reduce the risk of cardiovascular disease (CVD). Whether potential effects on cortisol contribute to these beneficial effects on cardiovascular health remains unclear. We therefore studied effects of long-term oral magnesium supplementation on glucocorticoid metabolism, specifically on the excretion of urinary cortisol, cortisone and their metabolites, as well as on the ratios reflecting enzymatic activity of 11β-hydroxysteroid dehydrogenases (11β-HSDs) and A-ring reductases.
Design
A post-hoc analysis of a randomized trial with allocation to a magnesium supplement (350 mg/day) or a placebo for 24-week.
Patients
Forty-nine overweight men and women, aged between 45 and 70 years.
Measurements
Cortisol, cortisone and their metabolites (tetrahydrocortisol [THF], allo-tetrahydrocortisol [allo-THF] and tetrahydrocortisone [THE]) were measured in 24-h urine samples. Enzymatic activities of 11β-HSD overall and of 11β-HSD type 2 were estimated as the urinary (THF + allo-THF [THFs])/THE and cortisol/cortisone ratios, respectively. A-ring reductase activity was assessed by ratios of THF/allo-THF, allo-THF/cortisol, THF/cortisol and THE/cortisone.
Results
After 24-week, urinary cortisol excretion was decreased in the magnesium group as compared with the placebo group (-32 nmol/24-h, 95% CI: -59; -5 nmol/24-h, p = .021). Ratios of THFs/THE and cortisol/cortisone were decreased following magnesium supplementation by 0.09 (95% CI: 0.02; 0.17, p = .018) and 0.10 (95% CI: 0.03; 0.17, p = .005), respectively. No effects were observed on A-ring reductase activity.
Conclusions
We observed a beneficial effect of magnesium supplementation towards a lower 24-h urinary cortisol excretion together with an increased activity of 11β-HSD type 2. Our findings may provide another potential mechanism by which increased magnesium intake lowers CVD risk (ClinicalTrials.gov identifier: NCT02235805).
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY-NC).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.